162P Efficacy and safety of GEMOX (gemcitabine plus oxaliplatin) plus sintilimab and bevacizumab as a conversion therapy in patients with initially unresectable biliary tract cancers (BTC): A single-arm, phase II study. (December 2022) - Zhang, N.; Zhou, J.; Wang, L.; Zhang, T.; Zhu, W.; Mao, A.; Pan, Q.; Lin, Z.; Wang, M.; Zhang, Y.; Feng, Y.; Xu, W.; et al.